Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Moderna Lifts Its Estimate for 2021 Coronavirus Vaccine Production by 20%

By Eric Volkman - Jan 4, 2021 at 7:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its new baseline case forecast for the year is 600 million doses.

If all goes according to its revised plan, Moderna ( MRNA 3.14% ) will have far more doses of its coronavirus vaccine on the market than formerly anticipated. The company announced Monday that it is lifting its base-case estimate for global production of mRNA-1273 in 2021 to 600 million doses from the previous forecast of 500 million.

Ideally, it will produce as many as 1 billion for the year. It is currently adding staff in order to reach such capacity.

Among other factors, Moderna is basing its new estimate on the initial rollouts of the coronavirus vaccine throughout North America. 

Patient receiving a vaccination shot.

Image source: Getty Images.

"Our effectiveness in providing early supply to the U.S. and Canadian governments and our ability to increase baseline production estimates for 2021 are both signals that our scale up of mRNA vaccine production is a success," Chief Technical Operations and Quality Officer Juan Andres said.

mRNA-1273 is the second coronavirus vaccine to receive emergency use authorization from the U.S. Food and Drug Administration. It and the first one, Pfizer and BioNTech's BNT162b2, are currently being distributed and administered in the country.

Attempting to cope with a still-worsening coronavirus outbreak, the U.S. government has contracted with Moderna for 200 million doses of mRNA-1273. The company believes it will have 100 million doses available in the country by the end of this current quarter. Roughly 18 million doses have been supplied to the government so far.

Moderna's update is good news both for the company and for this country, as widespread vaccination is needed as soon as possible. The company's stock rose by just under 7% on Monday, against the 1.5% decline of the S&P 500 index.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$310.95 (3.14%) $9.46
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.24 (2.26%) $1.20
BioNTech SE Stock Quote
BioNTech SE
BNTX
$343.54 (3.01%) $10.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.